1. Home
  2. KOPN vs LUNG Comparison

KOPN vs LUNG Comparison

Compare KOPN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$5.83

Market Cap

396.8M

Sector

Technology

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.66

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOPN
LUNG
Founded
1984
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Industrial Specialties
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.8M
57.9M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
KOPN
LUNG
Price
$5.83
$1.66
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$4.69
$5.38
AVG Volume (30 Days)
11.3M
501.7K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
103.03
7.64
EPS
N/A
N/A
Revenue
$1,530,311.00
$90,497,000.00
Revenue This Year
$50.07
$2.48
Revenue Next Year
$33.33
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
46.53
8.01
52 Week Low
$1.23
$1.13
52 Week High
$6.45
$3.88

Technical Indicators

Market Signals
Indicator
KOPN
LUNG
Relative Strength Index (RSI) 63.29 68.55
Support Level $2.13 $1.51
Resistance Level $6.45 $1.93
Average True Range (ATR) 0.61 0.10
MACD 0.01 0.04
Stochastic Oscillator 68.44 89.90

Price Performance

Historical Comparison
KOPN
LUNG

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: